Theravance Biopharma, Inc. - Ordinary Shares (TBPH) Covered Calls

Theravance Biopharma, Inc. is a biopharmaceutical company focused on the commercialization and development of respiratory medicines. Its primary asset is YUPELRI® (revefenacin), the first once-daily nebulized bronchodilator for COPD. The company also holds significant economic interests in TRELEGY Ellipta through Royalty Pharma. In 2026, the firm transitioned to a commercial-only focus following a major organizational restructuring.

You can sell covered calls on Theravance Biopharma, Inc. - Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for TBPH (prices last updated Tue 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Theravance Biopharma, Inc. (TBPH) is a streamlined, commercial-stage biopharmaceutical company. In early 2026, the organization underwent a transformative restructuring following Phase 3 clinical results for its pipeline candidate ampreloxetine. This shift involved winding down its legacy research and development (R&D) functions to focus entirely on its commercial respiratory portfolio and maximizing the value of its existing royalty streams. The company’s primary revenue driver is YUPELRI®, which is co-promoted with Viatris and holds a dominant position in the nebulized LAMA market for COPD patients.

The company’s financial model is characterized by high-margin royalty income and milestone payments. Beyond YUPELRI®, Theravance holds a substantial economic interest in TRELEGY Ellipta, global commercialization for which is led by GSK. In early 2026, the company successfully triggered a $100 million milestone payment from Royalty Pharma due to TRELEGY’s robust global sales performance. With a significant cash position (approximately $400 million as of Q1 2026) and no debt, the firm is currently operating under the guidance of a Strategic Review Committee tasked with evaluating alternatives to maximize shareholder value, including potential sale or further capital returns.

Competitive Landscape

TBPH competes in the respiratory maintenance market, specifically for COPD treatments. Following its pivot to a commercial-focused model, its primary competition comes from larger pharmaceutical firms with established inhaled therapies and specialized biotech companies in the pulmonary space.

1. GSK plc: While a partner on Trelegy, GSK’s broader respiratory portfolio represents both a benchmark and indirect competition for COPD patient share.
2. AstraZeneca: A leader in respiratory medicine with blockbuster inhaled therapies that compete for the same COPD maintenance patient population.
3. Catalyst Pharmaceuticals: A specialty peer focused on rare diseases and orphan drugs, often benchmarked against TBPH for its high-margin commercial model.
4. Viatris Inc.: TBPH’s primary commercial partner for YUPELRI®, whose broader generic and branded respiratory offerings influence TBPH’s market positioning.
5. Denali Therapeutics: A biotech peer that serves as a valuation benchmark for specialized biopharmaceutical firms during clinical and commercial transitions.

Strategic Outlook and Innovation

The strategic focus for 2026 is "Operational Efficiency and Value Realization." By cutting its cost base by 60% through the elimination of R&D expenses, the company expects to generate $60 to $70 million in annualized cash flow starting in Q3 2026. The 2026 roadmap is defined by the outcome of the Strategic Review Committee’s evaluation; management has signaled a "tax-efficient" approach to either returning its $400 million cash pile to shareholders or identifying a strategic acquirer interested in its durable YUPELRI® and TRELEGY cash flows.

Innovation at Theravance has shifted from drug discovery to "Commercial Optimization." The company is utilizing advanced market analytics to identify COPD patients who struggle with handheld inhalers due to dexterity or cognitive issues, positioning the nebulized YUPELRI® as the superior alternative. Additionally, the firm is enhancing its digital "Patient-First" support programs to improve therapy adherence and long-term persistency. By leveraging its deep expertise in the hospital and institutional sales channels, Theravance aims to maintain double-digit growth for YUPELRI® throughout 2026 while operating as a lean, cash-flow-positive enterprise.

Want more examples? TBI Covered Calls | TBT Covered Calls